Joint relief

 
Published: Saturday 04 July 2015

Celltech, the UK-based biotech firm, has tested a new drug against rheumatoid arthritis. Thegeneti- cally engineered drugCDP 571, is based on a synthetic antibody. The antibody blocks the action of the protein that attacks the joints of rheumatoid arthritis sufferers ( The Eastern Phannacist, Vo138, No 453). When tried on 36 patients, the ~drug mitigated the pain of affected joints and slowed the disease's progression just after eight weeks' treatment.

Subscribe to Weekly Newsletter :

Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.